Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: THY122
MIFTS: 57

Thyroid Gland Cancer

Categories: Cancer diseases, Endocrine diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Thyroid Gland Cancer

About this section

MalaCards integrated aliases for Thyroid Gland Cancer:

Name: Thyroid Gland Cancer 12 15
Malignant Neoplasm of Thyroid Gland 12 32
Neoplasm of the Thyroid Gland 29 6
Thyroid Gland Carcinoma 12 15
Thyroid Neoplasms 54 43
Thyroid Neoplasm 12 17
Malignant Tumour of Thyroid Gland 12
Head and Neck Cancer, Thyroid 12
Neoplasm of Thyroid Gland 12
Thyroid Gland Neoplasm 12
Thyroid Cancer 15

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Endocrine diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:1781 DOID:3963
ICD9CM 34 193
MeSH 43 D013964
SNOMED-CT 67 127018007 363478007
ICD10 32 C73
UMLS 71 C0007115 C0040136 C0549473
Sources

Summaries for Thyroid Gland Cancer

About this section
Disease Ontology : 12 An endocrine gland cancer located in the thryoid gland located in the neck below the thyroid cartilage.

MalaCards based summary : Thyroid Gland Cancer, also known as malignant neoplasm of thyroid gland, is related to thyroid gland follicular carcinoma and thyroid sarcoma. An important gene associated with Thyroid Gland Cancer is RET (Ret Proto-Oncogene), and among its related pathways/superpathways are Thyroid cancer and Aldosterone synthesis and secretion. The drugs Betamethasone and Fentanyl have been mentioned in the context of this disorder. Affiliated tissues include thyroid, lymph node and lung, and related phenotypes are Decreased viability and Decreased viability

Sources

Related Diseases for Thyroid Gland Cancer

About this section

Diseases related to Thyroid Gland Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 815)
# Related Disease Score Top Affiliating Genes
1 thyroid gland follicular carcinoma 33.3 TG RET PAX8 NRAS HRAS
2 thyroid sarcoma 33.1 TG PAX8
3 differentiated thyroid carcinoma 32.0 TG RET PAX8 NRAS KRAS HRAS
4 thyroid gland anaplastic carcinoma 32.0 TG RET PIK3CA PAX8 NRAS HRAS
5 thyroid carcinoma 31.9 TG RET PTCSC3 PIK3CA HRAS BRAF
6 thyroid tumor 31.9 TG RET PIK3CA NRAS KRAS HRAS
7 struma ovarii 31.8 TG RET KRAS BRAF
8 multinodular goiter 31.6 TG RET PAX8 HRAS
9 nodular goiter 31.5 TG RET HRAS BRAF
10 malignant struma ovarii 31.5 TG RET
11 hepatocellular carcinoma 31.4 UCA1 PVT1 PIK3CA PANDAR NRAS MALAT1
12 melanoma 31.4 UCA1 PVT1 PIK3CA NRAS MALAT1 KRAS
13 lung cancer 31.4 UCA1 RET PVT1 PIK3CA PANDAR NRAS
14 endometrial cancer 31.4 UCA1 RET PIK3CA PAX8 NRAS KRAS
15 neuroblastoma 31.4 RET PIK3CA NRAS MALAT1 HRAS HOTAIR
16 osteogenic sarcoma 31.4 UCA1 PVT1 PANDAR MALAT1 HOTAIR H19
17 kidney cancer 31.3 PVT1 PIK3CA MALAT1 HOTAIR H19 GAS5
18 thyroid cancer, nonmedullary, 1 31.3 MALAT1 HOTAIR H19
19 myeloma, multiple 31.3 UCA1 PVT1 NRAS MALAT1 KRAS HRAS
20 thyroiditis 31.3 TG RET HRAS BRAF
21 goiter 31.3 TG RET PAX8 HRAS
22 squamous cell carcinoma, head and neck 31.2 PIK3CA KRAS HRAS HOTAIR H19 GAS5
23 nasopharyngeal carcinoma 31.2 PVT1 PIK3CA NRAS MALAT1 LINC00312 HRAS
24 leukemia, chronic myeloid 31.1 UCA1 NRAS KRAS HRAS HOTAIR H19
25 thyroid cancer, nonmedullary, 2 31.1 TG PAX8 NRAS HRAS BRAF
26 adenocarcinoma 31.1 RET PIK3CA MALAT1 KRAS HRAS H19
27 adrenocortical carcinoma, hereditary 31.1 PIK3CA NRAS H19 BRAF
28 ovarian germ cell teratoma 31.1 TG RET
29 pancreatic cancer 31.1 UCA1 RET PVT1 PIK3CA MALAT1 KRAS
30 adenoma 31.1 TG RET PIK3CA KRAS BRAF
31 gastric cancer 31.1 UCA1 PVT1 PIK3CA PANDAR NRAS MALAT1
32 renal cell carcinoma, nonpapillary 31.1 UCA1 RET PVT1 PIK3CA PAX8 PANDAR
33 esophageal cancer 31.1 UCA1 PVT1 PIK3CA MALAT1 KRAS HRAS
34 breast cancer 31.1 UCA1 PVT1 PIK3CA PANDAR NRAS MALAT1
35 retinitis pigmentosa 11 31.1 UCA1 PVT1 HRAS HOTAIR
36 mature teratoma 31.1 TG KRAS BRAF
37 thyroid carcinoma, familial medullary 31.1 TG RET MALAT1 KRAS BRAF
38 follicular adenoma 31.0 TG RET PAX8 HRAS BRAF
39 papillary carcinoma 31.0 TG RET PAX8 BRAF
40 renal cell carcinoma, papillary, 1 31.0 RET PIK3CA PAX8 NRAS HRAS BRAF
41 thyroid gland medullary carcinoma 31.0 TG RET PAX8
42 benign struma ovarii 31.0 TG RET NRAS
43 malignant glioma 30.9 PVT1 MALAT1 HOTAIR H19 GAS5 CDKN2B-AS1
44 bladder cancer 30.9 UCA1 PVT1 PIK3CA PANDAR NRAS MALAT1
45 lynch syndrome 30.9 PIK3CA KRAS HRAS BRAF
46 sarcoma 30.9 RET PIK3CA NRAS KRAS HRAS HOTAIR
47 lung cancer susceptibility 3 30.9 RET PIK3CA NRAS MALAT1 KRAS HRAS
48 clear cell renal cell carcinoma 30.9 PVT1 PAX8 PANDAR MALAT1 KRAS
49 melanoma, cutaneous malignant 1 30.9 PIK3CA NRAS HRAS CDKN2B-AS1 BRAF
50 leukemia 30.9 NRAS KRAS HRAS HOTAIR GAS5 CDKN2B-AS1

Graphical network of the top 20 diseases related to Thyroid Gland Cancer:



Diseases related to Thyroid Gland Cancer
Sources

Symptoms & Phenotypes for Thyroid Gland Cancer

About this section

GenomeRNAi Phenotypes related to Thyroid Gland Cancer according to GeneCards Suite gene sharing:

26 (show all 13)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.03 HRAS KRAS PIK3CA BRAF
2 Decreased viability GR00055-A-2 10.03 HRAS KRAS PIK3CA BRAF
3 Decreased viability GR00055-A-3 10.03 KRAS
4 Decreased viability GR00106-A-0 10.03 KRAS
5 Decreased viability GR00221-A-1 10.03 HRAS KRAS NRAS PIK3CA RET
6 Decreased viability GR00221-A-2 10.03 HRAS KRAS PIK3CA RET
7 Decreased viability GR00221-A-3 10.03 HRAS NRAS
8 Decreased viability GR00221-A-4 10.03 PIK3CA RET BRAF
9 Decreased viability GR00249-S 10.03 BRAF
10 Decreased viability GR00301-A 10.03 KRAS RET BRAF
11 Decreased viability GR00381-A-1 10.03 KRAS BRAF
12 Decreased viability GR00402-S-2 10.03 PIK3CA RET
13 Decreased cell migration GR00055-A-3 9.13 BRAF HRAS PIK3CA
Sources

Drugs & Therapeutics for Thyroid Gland Cancer

About this section

Drugs for Thyroid Gland Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 359)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
2
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
3
Sodium citrate Approved, Investigational Phase 4 68-04-2
4
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
5
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
6
Acetaminophen Approved Phase 4 103-90-2 1983
7
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
8
Codeine Approved, Illicit Phase 4 76-57-3 5284371
9
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
10
Tyrosine Approved, Investigational, Nutraceutical Phase 4 60-18-4 6057
11 Anti-Asthmatic Agents Phase 4
12 Betamethasone acetate Phase 4
13 Citrate Phase 4
14 Anesthetics, Intravenous Phase 4
15 Narcotics Phase 4
16 Analgesics Phase 4
17 Analgesics, Opioid Phase 4
18 Respiratory System Agents Phase 4
19 Analgesics, Non-Narcotic Phase 4
20 Antitussive Agents Phase 4
21 Antipyretics Phase 4
22 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
23
Parathyroid hormone Approved, Investigational Phase 3 9002-64-6
24
Ropivacaine Approved Phase 3 84057-95-4 71273 175805
25
Cinacalcet Approved Phase 3 226256-56-0 156419
26 Calcium, Dietary Phase 3
27 Fibrin Tissue Adhesive Phase 3
28 Adrenergic beta-Agonists Phase 3
29 Vasoconstrictor Agents Phase 3
30 Sympathomimetics Phase 3
31 Bronchodilator Agents Phase 3
32 Mydriatics Phase 3
33 Hemostatics Phase 3
34 Coagulants Phase 3
35
Apatinib Phase 3 811803-05-1
36
Calcium Nutraceutical Phase 3 7440-70-2 271
37
Pemetrexed Approved, Investigational Phase 2 137281-23-3, 150399-23-8 60843 446556
38
leucovorin Approved Phase 2 58-05-9 6006 143
39
Loperamide Approved Phase 1, Phase 2 53179-11-6 3955
40
Somatostatin Approved, Investigational Phase 2 38916-34-6, 51110-01-1 53481605
41
Indinavir Approved Phase 2 150378-17-9 5362440
42
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
43
Axitinib Approved, Investigational Phase 2 319460-85-0 6450551
44
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
45
Panobinostat Approved, Investigational Phase 2 404950-80-7 6918837
46
Decitabine Approved, Investigational Phase 2 2353-33-5 451668
47
Azacitidine Approved, Investigational Phase 2 320-67-2 9444
48
Pioglitazone Approved, Investigational Phase 2 111025-46-8 4829
49
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
50
Pasireotide Approved Phase 2 396091-73-9 9941444

Interventional clinical trials:

(show top 50) (show all 663)
# Name Status NCT ID Phase Drugs
1 Total Thyroidectomy With Harmonic Scalpel® Versus Standard Surgery. Open Multicentric Randomized Controlled Trial Unknown status NCT00385983 Phase 4
2 The Use of Lu177 in the Treatment of Progressive and Unresectable Metastatic Medullary Thyroid Cancer Unknown status NCT01915485 Phase 4
3 Open-Label, Multi-Center, Randomized, Active-Controlled, Phase 4 Study of rAd-p53 Gene Mono-Therapy, With Concurrent Radioactive Iodine , or Combination With Surgery in Subjects With Advanced Malignant Thyroid Tumors Unknown status NCT00902122 Phase 4 rAd-p53 gene;p53 gene therapy
4 Evaluation of Potential Benefits of Using Steroids in the Postoperative Transient Hypoparathyroidism Total Thyroidectomy Unknown status NCT02652884 Phase 4 phosphate and betamethasone acetate, 2 mL.;saline 0.9% NaCl
5 Dose-dependent Effect of Fentanyl on Cough Attenuation During Emergence From General Anaesthesia Completed NCT01308320 Phase 4 fentanyl citrate;saline
6 Is it Possible to Increase Quality of Life, Using Recombinant TSH Instead of Withdrawal of Thyroid Hormone Treatment, Before Iodine Uptake in Patients With Thyroid Cancer? Completed NCT00604318 Phase 4 rhTSH
7 A Dosimetry Study of Radioiodine (131-I) Uptake Following the Administration of Thyrogen and Hypothyroid States During Thyroid Hormone Withdrawal Completed NCT00001730 Phase 4 Thyrogen
8 Diagnostic Accuracy Study of Indocyanine Green for Parathyroid Perfusion Assessment Completed NCT03969108 Phase 4 Indocyanine Green
9 Is the Routine Pressure Dressing After Thyroidectomy Necessary? A Prospective Randomized Controlled Study Completed NCT00400465 Phase 4
10 Prospective Single Arm Post Marketing Phase IV Study to Assess the Safety and Efficacy of Lenvatinib in Subjects With Locally Recurrent or Metastatic, Progressive, Radioiodine Refractory Differentiated Thyroid Cancer Recruiting NCT03573960 Phase 4 Lenvatinib
11 A Randomized, Double-blind Study To Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to a 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients Recruiting NCT01896479 Phase 4 Cabozantinib (XL184) 140 mg;Cabozantinib (XL184) 60 mg;Placebo tablet;Placebo capsule
12 An International, Randomised, Double-Blind, Two-Arm Study To Evaluate The Safety And Efficacy Of Vandetanib 150 And 300mg/Day In Patients With Unresectable Locally Advanced Or Metastatic Medullary Thyroid Carcinoma With Progressive Or Symptomatic Disease Active, not recruiting NCT01496313 Phase 4 300mg vandetanib;150mg vandetanib
13 Minimizing Narcotic Analgesics After Thyroid or Parathyroid Surgery Active, not recruiting NCT03469310 Phase 4 Acetaminophen 500Mg Cap;Tylenol #3 Oral Tablet;Tramadol
14 Levothyroxine Replacement With Liquid Gel Capsules or Tablets in Post-thyroidectomy Stage in Low Risk Differentiated Thyroid Cancer Patients Terminated NCT02946918 Phase 4 Levothyroxine
15 Therapeutic Role of Levothyroxine on the Patients With Atypia of Undetermined Significance (AUS) Goiter Withdrawn NCT02329379 Phase 4 Levothyroxine
16 Medico-Economic Comparison of Four Strategies of Radioiodine Ablation in Thyroid Carcinoma Patients - Estimabl Unknown status NCT00435851 Phase 3 Thyrogen, thyroid hormone withdrawal, iode 131
17 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors Unknown status NCT01373736 Phase 3 123I-meta-iodobenzylguanidine
18 Efficacy of Subfascial Approach in Thyroidectomy to Quality of Life in Thyroid Disease Patients: Prospective Randomized Study Completed NCT01616316 Phase 2, Phase 3
19 Phase 3 Study of Ropivacaine (With Epinephrine) in BABA Endoscopic and Robotic Thyroidectomy Completed NCT02112370 Phase 3 Ropivacaine with epinephrine injection
20 A Double-Blind Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer Completed NCT00984282 Phase 3 Sorafenib (Nexavar, BAY43-9006);Placebo
21 Follow-up of Thyroid Cancer Patients From Study THYR-008-00 Who Received Thyroid Remnant Ablation Using Either the Hypothyroid or the Thyrogen Method. Completed NCT00295763 Phase 3 Thyrogen (thyrotropin alfa for injection)
22 Value of Sentinel Lymph Node Biopsy to Lateral Neck Lymph Node in Thyroid Carcinoma: Prospective Study Completed NCT01137097 Phase 2, Phase 3
23 Prophylactic Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma: A Prospective Randomized Controlled Trial Completed NCT00795782 Phase 3
24 The Role of Sentinel Lymph Node Biopsy (SLNB) In the Management of Differentiated Thyroid Cancer Completed NCT00794053 Phase 3
25 A Randomized, Controlled, Open-Label, Multi-National Pilot Study of Thyroid Remnant Ablation Comparing the Safety and Ablation Rate Following 131I Administration Using Thyrogen® Versus the Safety and Ablation Rate Following 131I Administration in the Hypothyroid State Completed NCT00196729 Phase 3 Thyrogen + Radioiodine (131I)
26 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer Completed NCT01321554 Phase 3 Lenvatinib;Placebo;Lenvatinib
27 Decision Aid on Radioactive Iodine Treatment for Early Stage Papillary Thyroid Cancer (Randomized Controlled Trial) Completed NCT01083550 Phase 2, Phase 3
28 A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Compare the Efficacy and Safety of Anlotinib Versus Placebo in Patients With Medullary Thyroid Carcinoma(ALTER01031) Completed NCT02586350 Phase 2, Phase 3 Anlotinib;Placebo
29 A Phase I/II, Phase III and Extended Phase III Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Cancer or Suspected Cancer Completed NCT00123760 Phase 2, Phase 3
30 Efficacy of Fibrin Sealant to Reduce the Amount of Postoperative Drain in Patients With Harmonic Scalpel-assisted Total Thyroidectomy With Anterior Compartment Neck Dissections Completed NCT01126060 Phase 3 Usage of Fibrin sealant
31 Phase 3 Trial of Adjuvant External Beam Radiotherapy for Locally Invasive Differentiated Thyroid Carcinoma Completed NCT00144079 Phase 3
32 Cinacalcet Actions in Familial Primary Hyperparathyroidism Completed NCT00325104 Phase 3
33 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects With Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-Targeted Therapy Recruiting NCT03690388 Phase 3 Cabozantinib;Placebo
34 A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531) Recruiting NCT04211337 Phase 3 Selpercatinib;Cabozantinib;Vandetanib
35 Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients Recruiting NCT01398085 Phase 2, Phase 3
36 A Multicenter, Randomized, Double-Blind,Placebo-controlled,Phase 3 Trial of Donafenib in 131IRefractory Differentiated Thyroid Cancer Recruiting NCT03602495 Phase 3 Donafenib;Placebo
37 Multicentric Phase III Trial Comparing Two Strategies in Intermediate-risk Differentiated Thyroid Cancer Patients: Systematic Radioiodine Administration (3.7 GBq I131 After rhTSH) Versus Decision of Radioiodine Treatment Guided by a Post-operative Work-up Based on Serum Tg Values and Diagnostic RAI Scintigraphy Recruiting NCT04290663 Phase 3 Systematic RAI-treatment
38 Differentiated Thyroid Cancer: is There a Need for Radioiodine Ablation in Low Risk Patients? Recruiting NCT01837745 Phase 3 rhTSH stimulation;I131
39 Sentinel Lymph Node Biopsy in the Thyroid Carcinoma; Randomized, Prospective Study Recruiting NCT01149161 Phase 2, Phase 3
40 Phase â…¡ Non-randomized Multicenter Controlled Trial About Effect of Remnant Ablation Therapy on the Recurrence in Low-risk Differentiated Thyroid Cancer Patients Active, not recruiting NCT02418247 Phase 2, Phase 3 I131;I123
41 A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Compare the Efficacy and Safety of Anlotinib Versus Placebo in Patients With 131I-Refractory Differentiated Thyroid Cancer(ALTER01032) Active, not recruiting NCT02586337 Phase 2, Phase 3 Anlotinib;Placebo
42 An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMATM) Versus Placebo in Subjects With Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer Active, not recruiting NCT00410761 Phase 3 ZD6474 (Vandetanib)
43 An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 Versus Placebo in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer Active, not recruiting NCT00704730 Phase 3 XL184;Placebo
44 A Randomized, Double-Blind, Placebo-Controlled Study of Apatinib in Locally Advanced or Metastatic Radioactive Iodine-refractory Differentiated Thyroid Cancer Active, not recruiting NCT03048877 Phase 3 Apatinib Oral Tablet;Placebo Oral Tablet
45 A Randomized,Int.,Open-Label Phase III Study to Assess the Effect of a Patient Outreach Program on the Percentage of Time Patients With Locally Advanced or Metastatic MTC Experience Grade 2 or Higher AEs in the First 12 Months of Treatment With Vandetanib Active, not recruiting NCT01298323 Phase 3 Vandetanib
46 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131 I-Refractory Differentiated Thyroid Cancer in China Active, not recruiting NCT02966093 Phase 3 Lenvatinib;Placebo
47 Multicentre Randomised Trial of High Dose Versus Low Dose Radioiodine, With or Without Recombinant Human Thyroid Stimulating Hormone, for Remnant Ablation Following Surgery for Differentiated Thyroid Cancer [HILO] Active, not recruiting NCT00415233 Phase 3
48 A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSAâ„¢; SAR390530 (Formerly AstraZeneca ZD6474)) 300 mg in Patients With Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy. Active, not recruiting NCT01876784 Phase 3 Vandetanib (SAR390530);Placebo
49 Effect of the Radioiodine Dose in Thyroid Ablation- A Randomized Comparison of 1110 MBq to 3700 MBq Active, not recruiting NCT00115895 Phase 3 Radioactive iodine
50 ESTIMation of the ABiLity of Prophylactic Central Compartment Neck Dissection to Modify Outcomes in Low-risk Differentiated Thyroid Cancer Not yet recruiting NCT03570021 Phase 3

Search NIH Clinical Center for Thyroid Gland Cancer

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Interferon Alfa-2b
lenvatinib
levothyroxine
Levothyroxine Sodium
liothyronine
liothyronine sodium
sorafenib
Thyroglobulin
THYROID (BEEF)
thyroid (USP)
THYROID PWDR
thyrotropin alfa
Vandetanib

Cochrane evidence based reviews: thyroid neoplasms

Sources

Genetic Tests for Thyroid Gland Cancer

About this section

Genetic tests related to Thyroid Gland Cancer:

# Genetic test Affiliating Genes
1 Neoplasm of the Thyroid Gland 29
Sources

Anatomical Context for Thyroid Gland Cancer

About this section

MalaCards organs/tissues related to Thyroid Gland Cancer:

40
Thyroid, Lymph Node, Lung, Breast, Bone, Testes, Prostate
Sources

Publications for Thyroid Gland Cancer

About this section

Articles related to Thyroid Gland Cancer:

(show top 50) (show all 1637)
# Title Authors PMID Year
1
Expression of thyroid transcription factor-1 in colorectal carcinoma. 54 61
20042854 2010
2
Thioredoxin and thioredoxin reductase expression in thyroid cancer depends on tumour aggressiveness. 61 54
20392995 2010
3
Differential expression of galectin-3, CK19, HBME1, and Ret oncoprotein in the diagnosis of thyroid neoplasms by fine needle aspiration biopsy. 61 54
19826479 2009
4
Epigenetic silencing of TTF-1/NKX2-1 through DNA hypermethylation and histone H3 modulation in thyroid carcinomas. 54 61
19506552 2009
5
The significance of Galectin-3 expression in the immunocytochemical evaluation of thyroid fine needle aspiration cytology. 61 54
18415710 2008
6
Differentiating alternative splice variant patterns of human telomerase reverse transcriptase in thyroid neoplasms. 61 54
18816183 2008
7
ECM1 expression in thyroid tumors--a comparison of real-time RT-PCR and IHC. 61 54
18374945 2008
8
Thyroid transcription factor-1 expression in ovarian epithelial neoplasms. 61 54
18246044 2008
9
Combined immunostaining with galectin-3, fibronectin-1, CITED-1, Hector Battifora mesothelial-1, cytokeratin-19, peroxisome proliferator-activated receptor-{gamma}, and sodium/iodide symporter antibodies for the differential diagnosis of non-medullary thyroid carcinoma. 61 54
18299472 2008
10
Thyroid transcription factor-1 expression in endometrial and endocervical adenocarcinomas. 54 61
18059234 2007
11
Paraganglioma of the thyroid: report of a male case with ultrasonographic imagings, cytologic, histologic, and immunohistochemical features. 61 54
17614779 2007
12
Association of nuclear, cytoplasmic expression of galectin-3 with beta-catenin/Wnt-pathway activation in thyroid carcinoma. 54 61
17515507 2007
13
Accumulation of p27(kip1) is associated with cyclin D3 overexpression in the oxyphilic (Hurthle cell) variant of follicular thyroid carcinoma. 61 54
16798934 2007
14
Carcinoma showing thymus-like differentiation of the thyroid (CASTLE): a comparative study: evidence of thymic differentiation and solid cell nest origin. 54 61
16861971 2006
15
CpG island methylation of tumor-related promoters occurs preferentially in undifferentiated carcinoma. 54 61
16889486 2006
16
Utility of galectin 3 expression in thyroid aspirates as a diagnostic marker in differentiating benign from malignant thyroid neoplasms. 54 61
17001889 2006
17
[Comparison of CD15, galectin-3 and HBME-1 expression in follicular thyroid neoplasms]. 54 61
17006830 2006
18
Diagnostic and extent of disease multigene assay for malignant thyroid neoplasms. 61 54
16688775 2006
19
Simultaneous immunohistochemical expression of HBME-1 and galectin-3 differentiates papillary carcinomas from hyperfunctioning lesions of the thyroid. 61 54
16722927 2006
20
Diagnostic and prognostic value of cell-cycle regulatory genes in malignant thyroid neoplasms. 54 61
16547620 2006
21
Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasms. 61 54
16405677 2006
22
Diagnostic and prognostic value of angiogenesis-modulating genes in malignant thyroid neoplasms. 54 61
16360397 2005
23
Cyclin D1 expression in primary thyroid carcinomas. 54 61
16380680 2005
24
Galectin-3 immunodetection in follicular thyroid neoplasms: a prospective study on fine-needle aspiration samples. 61 54
16251880 2005
25
ECM1 and TMPRSS4 are diagnostic markers of malignant thyroid neoplasms and improve the accuracy of fine needle aspiration biopsy. 61 54
16135921 2005
26
Quantitative assessment of promoter methylation profiles in thyroid neoplasms. 61 54
15840741 2005
27
Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application. 61 54
15947105 2005
28
Telomerase activity in thyroid neoplasms evaluated by the expression of human telomerase reverse transcriptase (hTERT). 61 54
15816620 2005
29
Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasms. 61 54
15500653 2004
30
PAX8 and peroxisome proliferator-activated receptor gamma 1 gene expression status in benign and malignant thyroid tissues. 61 54
15362967 2004
31
BRAF T1796A transversion mutation in various thyroid neoplasms. 61 54
15001635 2004
32
Early occurrence of RASSF1A hypermethylation and its mutual exclusion with BRAF mutation in thyroid tumorigenesis. 61 54
14996725 2004
33
S100A4 expression is an early event of papillary carcinoma of the thyroid. 54 61
15713996 2004
34
Maspin expression is directly associated with biological aggressiveness of thyroid carcinoma. 54 61
15009909 2004
35
Silencing of the maspin gene by promoter hypermethylation in thyroid cancer. 54 61
12964023 2003
36
Galectin-3 expression in hyalinizing trabecular tumors of the thyroid gland. 54 61
12657934 2003
37
Human telomerase reverse transcriptase (hTERT) gene expression in FNA samples from thyroid neoplasms. 54 61
12618337 2003
38
Differential expression of galectin-3 in papillary projections of malignant and non-malignant hyperplastic thyroid lesions. 61 54
15179758 2003
39
Galectin-3 messenger ribonucleic acid and protein are expressed in benign thyroid tumors. 61 54
12364477 2002
40
Glucose transporter 1 gene expression is related to thyroid neoplasms with an unfavorable prognosis: an immunohistochemical study. 61 54
12481939 2002
41
Utility of thyroid transcription factor-1 and cytokeratin 20 in identifying the origin of metastatic carcinomas of cervical lymph nodes. 54 61
12172048 2002
42
Expression of thyroid transcription factor-1 in strumal carcinoid and struma ovarii: an immunohistochemical study. 54 61
12167104 2002
43
P63 expression in papillary and anaplastic carcinomas of the thyroid gland: lack of an oncogenetic role in tumorigenesis and progression. 61 54
12234063 2002
44
Cytoplasmic accumulation of alpha-catenin in thyroid neoplasms. 61 54
11400246 2001
45
[Tumor markers for endocrine neoplasms]. 61 54
11329795 2001
46
Differential reactivity for galectin-3 in Hürthle cell adenomas and carcinomas. 54 61
11740048 2001
47
Thyroid transcription factor-1, thyroglobulin, cytokeratin 7, and cytokeratin 20 in thyroid neoplasms. 61 54
10981870 2000
48
Assessment of ret/PTC-1 rearrangements in neoplastic thyroid tissue using TaqMan RT-PCR. 61 54
10951397 2000
49
Galectin-3 expression in various thyroid neoplasms and its possible role in metastasis formation. 61 54
10821488 2000
50
Thyroid transcription factor-1 is expressed in extrapulmonary small cell carcinomas but not in other extrapulmonary neuroendocrine tumors. 54 61
10757334 2000
Sources

Variations for Thyroid Gland Cancer

About this section

ClinVar genetic disease variations for Thyroid Gland Cancer:

6 (show all 41) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 KRAS NM_033360.4(KRAS):c.34G>C (p.Gly12Arg)SNV Pathogenic 12579 rs121913530 12:25398285-25398285 12:25245351-25245351
2 KRAS NM_033360.4(KRAS):c.38G>A (p.Gly13Asp)SNV Pathogenic 12580 rs112445441 12:25398281-25398281 12:25245347-25245347
3 KRAS NM_033360.4(KRAS):c.35G>A (p.Gly12Asp)SNV Pathogenic 12582 rs121913529 12:25398284-25398284 12:25245350-25245350
4 KRAS NM_033360.4(KRAS):c.35G>T (p.Gly12Val)SNV Pathogenic 12583 rs121913529 12:25398284-25398284 12:25245350-25245350
5 KRAS NM_033360.4(KRAS):c.34G>A (p.Gly12Ser)SNV Pathogenic 12584 rs121913530 12:25398285-25398285 12:25245351-25245351
6 KRAS NM_033360.4(KRAS):c.37G>C (p.Gly13Arg)SNV Pathogenic 12593 rs121913535 12:25398282-25398282 12:25245348-25245348
7 HRAS NM_005343.4(HRAS):c.35G>T (p.Gly12Val)SNV Pathogenic 12600 rs104894230 11:534288-534288 11:534288-534288
8 HRAS NM_005343.4(HRAS):c.34G>A (p.Gly12Ser)SNV Pathogenic 12602 rs104894229 11:534289-534289 11:534289-534289
9 HRAS NM_005343.4(HRAS):c.35G>C (p.Gly12Ala)SNV Pathogenic 12603 rs104894230 11:534288-534288 11:534288-534288
10 HRAS NM_005343.4(HRAS):c.37G>T (p.Gly13Cys)SNV Pathogenic 12606 rs104894228 11:534286-534286 11:534286-534286
11 HRAS NM_005343.4(HRAS):c.34G>T (p.Gly12Cys)SNV Pathogenic 12613 rs104894229 11:534289-534289 11:534289-534289
12 RET NM_020975.6(RET):c.1902C>G (p.Cys634Trp)SNV Pathogenic 13918 rs77709286 10:43609950-43609950 10:43114502-43114502
13 RET NM_020975.6(RET):c.2753T>C (p.Met918Thr)SNV Pathogenic 13919 rs74799832 10:43617416-43617416 10:43121968-43121968
14 BRAF NM_001374258.1(BRAF):c.1921A>G (p.Lys641Glu)SNV Pathogenic 13966 rs121913364 7:140453134-140453134 7:140753334-140753334
15 KRAS NM_033360.4(KRAS):c.182A>G (p.Gln61Arg)SNV Pathogenic 45115 rs121913240 12:25380276-25380276 12:25227342-25227342
16 KRAS NM_033360.4(KRAS):c.182A>T (p.Gln61Leu)SNV Pathogenic 45116 rs121913240 12:25380276-25380276 12:25227342-25227342
17 KRAS NM_033360.4(KRAS):c.181C>A (p.Gln61Lys)SNV Pathogenic 177777 rs121913238 12:25380277-25380277 12:25227343-25227343
18 NRAS NM_002524.5(NRAS):c.182A>C (p.Gln61Pro)SNV Pathogenic 280409 rs11554290 1:115256529-115256529 1:114713908-114713908
19 NRAS NM_002524.5(NRAS):c.183A>T (p.Gln61His)SNV Pathogenic 373003 rs121913255 1:115256528-115256528 1:114713907-114713907
20 KRAS NM_033360.4(KRAS):c.437C>T (p.Ala146Val)SNV Pathogenic 375962 rs1057519725 12:25378561-25378561 12:25225627-25225627
21 KRAS NM_033360.4(KRAS):c.37G>A (p.Gly13Ser)SNV Pathogenic 375968 rs121913535 12:25398282-25398282 12:25245348-25245348
22 KRAS NM_033360.4(KRAS):c.182A>C (p.Gln61Pro)SNV Pathogenic/Likely pathogenic 375966 rs121913240 12:25380276-25380276 12:25227342-25227342
23 KRAS NM_033360.4(KRAS):c.34G>T (p.Gly12Cys)SNV Pathogenic/Likely pathogenic 12578 rs121913530 12:25398285-25398285 12:25245351-25245351
24 PIK3CA NM_006218.4(PIK3CA):c.3129G>A (p.Met1043Ile)SNV Pathogenic/Likely pathogenic 179173 rs121913283 3:178952074-178952074 3:179234286-179234286
25 NRAS NM_002524.5(NRAS):c.182A>T (p.Gln61Leu)SNV Pathogenic/Likely pathogenic 375874 rs11554290 1:115256529-115256529 1:114713908-114713908
26 HRAS , LRRC56 NM_005343.4(HRAS):c.34G>C (p.Gly12Arg)SNV Pathogenic/Likely pathogenic 375961 rs104894229 11:534289-534289 11:534289-534289
27 KRAS NM_033360.4(KRAS):c.183A>T (p.Gln61His)SNV Pathogenic/Likely pathogenic 45117 rs17851045 12:25380275-25380275 12:25227341-25227341
28 HRAS NM_005343.4(HRAS):c.37G>C (p.Gly13Arg)SNV Pathogenic/Likely pathogenic 35554 rs104894228 11:534286-534286 11:534286-534286
29 BRAF NM_001374258.1(BRAF):c.1922A>C (p.Lys641Thr)SNV Pathogenic/Likely pathogenic 44818 rs397507484 7:140453133-140453133 7:140753333-140753333
30 PIK3CA NM_006218.4(PIK3CA):c.353G>A (p.Gly118Asp)SNV Pathogenic/Likely pathogenic 156446 rs587777790 3:178917478-178917478 3:179199690-179199690
31 HRAS NM_005343.4(HRAS):c.182A>G (p.Gln61Arg)SNV Likely pathogenic 160364 rs121913233 11:533874-533874 11:533874-533874
32 KRAS NM_033360.4(KRAS):c.38G>T (p.Gly13Val)SNV drug response 45124 rs112445441 12:25398281-25398281 12:25245347-25245347
33 HRAS , LRRC56 NM_005343.4(HRAS):c.182A>T (p.Gln61Leu)SNV Likely pathogenic 376033 rs121913233 11:533874-533874 11:533874-533874
34 BRAF NM_004333.6(BRAF):c.1803A>C (p.Lys601Asn)SNV Likely pathogenic 376286 rs121913365 7:140453132-140453132 7:140753332-140753332
35 HRAS NM_005343.4(HRAS):c.183G>T (p.Gln61His)SNV Likely pathogenic 376318 rs121913496 11:533873-533873 11:533873-533873
36 HRAS , LRRC56 NM_005343.4(HRAS):c.182A>C (p.Gln61Pro)SNV Likely pathogenic 376322 rs121913233 11:533874-533874 11:533874-533874
37 HRAS , LRRC56 NM_005343.4(HRAS):c.181C>G (p.Gln61Glu)SNV Likely pathogenic 376444 rs28933406 11:533875-533875 11:533875-533875
38 PIK3CA NM_006218.4(PIK3CA):c.3127A>G (p.Met1043Val)SNV Likely pathogenic 376485 rs1057519936 3:178952072-178952072 3:179234284-179234284
39 PIK3CA NM_006218.4(PIK3CA):c.3128T>C (p.Met1043Thr)SNV Likely pathogenic 376486 rs1057519937 3:178952073-178952073 3:179234285-179234285
40 PIK3CA NM_006218.4(PIK3CA):c.3127A>T (p.Met1043Leu)SNV Likely pathogenic 376487 rs1057519936 3:178952072-178952072 3:179234284-179234284
41 AKT1 NM_005163.2(AKT1):c.49G>A (p.Glu17Lys)SNV Uncertain significance 13983 rs121434592 14:105246551-105246551 14:104780214-104780214

Copy number variations for Thyroid Gland Cancer from CNVD:

7 (show all 22)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 48476 11 1 43400000 Gain Thyroid cancer
2 75266 13 18400000 72100000 Loss Thyroid cancer
3 80538 13 93800000 114142980 Loss Thyroid cancer
4 85051 14 37800000 43500000 Copy number FOXA1 Thyroid cancer
5 96631 15 90931472 91045475 Amplificationlication IQGAP1 Thyroid cancer
6 111285 17 35400000 68400000 Gain Thyroid cancer
7 120295 18 23300000 71300000 Loss Thyroid cancer
8 150420 20 1 27100000 Amplification Thyroid cancer
9 151957 20 27100000 62435964 Amplification Thyroid cancer
10 153452 20 37100000 62435964 Gain Thyroid cancer
11 171643 3 170900000 182700000 Gain PIK3CA Thyroid cancer
12 171644 3 170900000 182700000 Gain PIK3CA Thyroid cancer
13 191662 5 1 45800000 Amplification Thyroid cancer
14 191664 5 1 45800000 Gain Thyroid cancer
15 200481 5 55800000 180857866 Gain Thyroid cancer
16 201091 5 65300000 159900000 Amplification Thyroid cancer
17 217036 7 1 158821424 Amplification Thyroid cancer
18 230743 8 1 19100000 Loss Thyroid cancer
19 236403 8 16100000 117700000 Amplification Thyroid cancer
20 236404 8 16100000 146274826 Gain Thyroid cancer
21 261707 X 24900000 59500000 Loss Thyroid cancer
22 303365 21 26028751 26066642 Deletion NRF2 Thyroid cancer
Sources

Expression for Thyroid Gland Cancer

About this section
Search GEO for disease gene expression data for Thyroid Gland Cancer.
Sources

Pathways for Thyroid Gland Cancer

About this section

Pathways related to Thyroid Gland Cancer according to KEGG:

36
# Name Kegg Source Accession
1 Thyroid cancer hsa05216

Pathways related to Thyroid Gland Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 92)
# Super pathways Score Top Affiliating Genes
1
Aldosterone synthesis and secretion 36
Show member pathways
 12.95 TG PAX8 NRAS KRAS HRAS BRAF
2
Regulation of lipid metabolism Insulin signaling-generic cascades 22
Show member pathways
 12.94 PIK3CA NRAS KRAS HRAS BRAF
3
Focal Adhesion 36 1
Show member pathways
 12.94 PIK3CA NRAS KRAS HRAS BRAF
4
MAPK Erk Pathway 66
Show member pathways
 12.92 PIK3CA NRAS KRAS HRAS BRAF
5
CCR5 Pathway in Macrophages 63
Show member pathways
 12.92 PIK3CA NRAS KRAS HRAS BRAF
6
NFAT and Cardiac Hypertrophy 63
Show member pathways
 12.9 PIK3CA NRAS KRAS HRAS BRAF
7
Development Angiotensin activation of ERK 22
Show member pathways
 12.88 PIK3CA NRAS KRAS HRAS BRAF
8
Gastric cancer 36
Show member pathways
 12.81 PIK3CA NRAS KRAS HRAS BRAF
9
Endometrial cancer 36
Show member pathways
 12.8 RET PIK3CA PAX8 NRAS KRAS HRAS
10
Ras signaling pathway 36
Show member pathways
 12.79 PIK3CA NRAS KRAS HRAS BRAF
11
Development HGF signaling pathway 22
Show member pathways
 12.77 PIK3CA NRAS KRAS HRAS BRAF
12
Pathways in cancer 36
12.75 RET PIK3CA PAX8 NRAS KRAS HRAS
13
Glioma 36
Show member pathways
 12.73 PIK3CA NRAS KRAS HRAS BRAF
14
Regulation of actin cytoskeleton 36 1
12.69 PIK3CA NRAS KRAS HRAS BRAF
15
ErbB signaling pathway 36 1
Show member pathways
 12.67 PIK3CA NRAS KRAS HRAS BRAF
16
Negative regulation of FGFR3 signaling 65
Show member pathways
 12.61 PIK3CA NRAS KRAS HRAS BRAF
17
Immune response Role of DAP12 receptors in NK cells 22
Show member pathways
 12.56 PIK3CA NRAS KRAS HRAS BRAF
18
mTOR signaling pathway (KEGG) 36
Show member pathways
 12.55 PIK3CA NRAS KRAS HRAS BRAF
19
VEGF Signaling 66
Show member pathways
 12.53 PIK3CA NRAS KRAS HRAS
20
Oxytocin signaling pathway 36
Show member pathways
 12.53 NRAS KRAS HRAS BRAF
21
MET promotes cell motility 65
Show member pathways
 12.53 PIK3CA NRAS KRAS HRAS
22
Prolactin Signaling Pathway 36 1
Show member pathways
 12.51 PIK3CA NRAS KRAS HRAS
23
B Cell Receptor Signaling Pathway (sino) 66
Show member pathways
 12.49 PIK3CA NRAS KRAS HRAS
24
Apoptosis Pathway 70
Show member pathways
 12.48 PIK3CA NRAS KRAS HRAS
25
RANK Signaling in Osteoclasts 63
Show member pathways
 12.46 NRAS KRAS HRAS BRAF
26
Phospholipase D signaling pathway 36
Show member pathways
 12.45 PIK3CA NRAS KRAS HRAS
27
G-protein signaling RAC1 in cellular process 22
Show member pathways
 12.45 PIK3CA NRAS KRAS HRAS BRAF
28
Development FGFR signaling pathway 22
Show member pathways
 12.45 PIK3CA NRAS KRAS HRAS
29
Development VEGF signaling via VEGFR2 - generic cascades 22
Show member pathways
 12.44 PIK3CA KRAS HRAS BRAF
30
B cell receptor signaling pathway (KEGG) 36
Show member pathways
 12.43 PIK3CA NRAS KRAS HRAS BRAF
31
Human T-cell leukemia virus 1 infection 36
12.39 PIK3CA NRAS KRAS HRAS
32
CNTF Signaling 63
Show member pathways
 12.38 NRAS KRAS HRAS BRAF
33
Signaling by ERBB2 65
Show member pathways
 12.37 PIK3CA NRAS KRAS HRAS
34
Viral carcinogenesis 36
12.35 PIK3CA NRAS KRAS HRAS
35
Paradoxical activation of RAF signaling by kinase inactive BRAF 65
Show member pathways
 12.35 NRAS KRAS HRAS BRAF
36
G-protein signaling Ras family GTPases in kinase cascades (scheme) 22
Show member pathways
 12.35 NRAS KRAS HRAS BRAF
37
Proteoglycans in cancer 36
12.31 PIK3CA NRAS KRAS HRAS BRAF
38
Axon guidance 36
12.29 PIK3CA NRAS KRAS HRAS
39
MAPK Signaling: Mitogens 64
Show member pathways
 12.29 PIK3CA NRAS KRAS HRAS BRAF
40
Cell surface interactions at the vascular wall 65
Show member pathways
 12.28 PIK3CA NRAS KRAS HRAS
41
Signaling by FGFR2 65
Show member pathways
 12.28 PIK3CA NRAS KRAS HRAS BRAF
42
C-type lectin receptor signaling pathway 36
Show member pathways
 12.27 PIK3CA NRAS KRAS HRAS
43
Development EGFR signaling pathway 22
Show member pathways
 12.24 PIK3CA NRAS KRAS HRAS BRAF
44
Signaling by FGFR2 in disease 65
Show member pathways
 12.22 PIK3CA NRAS KRAS HRAS
45
Cellular senescence (KEGG) 36
12.21 PIK3CA NRAS KRAS HRAS
46
NGF Pathway 63
Show member pathways
 12.2 NRAS KRAS HRAS BRAF
47
Longevity regulating pathway 36
Show member pathways
 12.19 PIK3CA NRAS KRAS HRAS
48
Development EGFR signaling via small GTPases 22
Show member pathways
 12.19 PIK3CA NRAS KRAS HRAS
49
GDNF-Family Ligands and Receptor Interactions 63
Show member pathways
 12.18 RET PIK3CA NRAS KRAS HRAS
50
Signaling pathways regulating pluripotency of stem cells 36
12.17 PIK3CA NRAS KRAS HRAS
Sources

GO Terms for Thyroid Gland Cancer

About this section

Biological processes related to Thyroid Gland Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.77 RET KRAS HRAS CDKN2B-AS1 BRAF
2 liver development GO:0001889 9.58 PIK3CA KRAS HRAS
3 Ras protein signal transduction GO:0007265 9.5 NRAS KRAS HRAS
4 negative regulation of neuron apoptotic process GO:0043524 9.46 PIK3CA KRAS HRAS BRAF
5 MAPK cascade GO:0000165 9.35 RET NRAS KRAS HRAS BRAF
6 response to isolation stress GO:0035900 9.26 KRAS HRAS
7 thyroid gland development GO:0030878 8.8 TG PAX8 BRAF

Molecular functions related to Thyroid Gland Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 GDP binding GO:0019003 8.8 NRAS KRAS HRAS
Sources

Sources for Thyroid Gland Cancer

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....